- January 20, 2021
- Posted by: Bastion team
- Category: Markets
(RTTNews) – Shares of clinical-stage drug discovery company Lixte Biotechnology Holdings, Inc. (LIXT) are rising more than 15% Tuesday morning after the company announced an agreement with cancer research and treatment center, City of Hope to begin Phase 1b study of LB-100 in small cell lung cancer.
The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).
LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC.
LIXT, currently at $3.61, has traded in the range of $0.80- $7.86 in the last one year.
Bastion Balance Seoul, Korea.